Ariel Perez

MD Hematology Oncology BMT Cell Therapy Miami Cancer Center. Former Fellow Moffitt Cancer Center - Views are my own

[Ariel Perez @app1279]

Some days remind you why we do this. Our patients’ courage never ceases to inspire. Honored to give a survivor medal to a brave patient—2 years post-ASCT for MCL (image posted with permission) @BaptistHealthSF

[Ariel Perez @app1279]

Very productive @FLASCO_ORG Business of Oncology Summit yesterday. It was a pleasure to participate alongside such an outstanding faculty group.

Don’t miss the education sessions at the Spring Congress—now underway.

[Ariel Perez @app1279]

@MarcoLDavila You sure don’t get that view in Buffalo😅

[Ariel Perez @app1279]

@HayderSaeed_MD @OncoDailyBio Congrats Hayder

[Herbert Wertheim Cancer Institute Research @MiamiCancerInst]

Registration is open for the Miami Cancer Institute Immunotherapies Summit for Hematologic Malignancies 🗓️ Mar 6–7, 2026 https://t.co/yYslUdt10D

#HemeOnc #CART #AML #Lymphoma #MultipleMyeloma

[Ariel Perez @app1279]

Great MRD in AML session #Tandem26 Loved the practical insights from Dr Nadia Bambace and @SagheerTiba Lots of takeaways for real world practice. Privileged to work with them @BaptistHealthSF

[Ariel Perez @app1279]

@RahulBanerjeeMD @Bethfaiman @JCO_ASCO @jmikhaelmd @SLentzsch Congrats Rahul. Great article

[JCO Oncology Practice @JCOOP_ASCO]

Outpatient Administration of Bispecific Antibody Therapy for Hematologic Malignancies: A Practical Guide. Co-authored by @DholariaMD.

Read the full article. https://t.co/lxv84tYNIG

[Ariel Perez @app1279]

@Dr_AmerZeidan @ASH_hematology 2020 was my first ASH (virtual) and then in 2021 got my first in person poster photo (could not find the unmasked version)

[Ariel Perez @app1279]

Phase 1b double-dose axi-cel presented by Caroline Lee (Stanford). High response rates with axi-cel 2, greater CAR AUC with less exhausted phenotypes and low added toxicity. Excellent talk!

[Ariel Perez @app1279]

Excited to be in Orlando for #ASH25. A special thanks to the organizers for the birthday gift. My collection of heme socks continues to grow!

[Ajay Major, MD, MBA @majorajay]

CAR-T in PCNSL #lymsm
- 67 pts, 25% CSF+, 12% eye+
- 57% axicel, 30% tisacel
- 58% CR, 1-yr PFS 50%, 1-yr OS 66%
- 2-yr RFS better if CR/PR at CAR infusion: 56% vs 28%
- 27% G3+ ICANS!
Almost all got bridging; would love to know which agents.
https://t.co/b09lNb884E

[Ash Alizadeh, MD/PhD 🇺🇸 @AshAlizadeh]

An honor and a privilege to have been part of this collaborative study across frontline DLBCL trials.

[David Russler-Germain, MD/PhD @dgermain21]

But perhaps the BIGGEST change that will affect my interpretation of trials is new neutropenia cutoffs!

v5 = Gr1 is LLN to 1500, Gr2 is 1000-1500, Gr3 is 500-1000, Gr4 is <500...

Now in v6 = Gr1 is 1000-1500, Gr2 is 500-1000, Gr3 is 100-500, Gr4 is <100!!!

[Jordan Gauthier @drjgauthier]

I was lucky to lead this @CIBMTR analysis just published in @AjHematology 👇
https://t.co/5JtisXr3Tz
🔑 findings:
💡 CD19 CAR T-cell therapy leads to high rates of durable responses in patients with primary mediastinal large B-cell lymphoma (PMBCL): ORR 79% CRR 68% 2-year PFS 58.6%. Outcomes may be superior compared to other LBCL subtypes.
💡We observed significantly lower relapse rates in patients exposed to immune checkpoint inhibitors prior to CAR T-cell therapy with ~50% absolute reduction in relapse incidence in ICI-exposed (2-year cumulative incidence of relapse: 21.7%) compared to ICI-naive patients (41.6%).
💡Prior ICI exposure was not associated with higher rates or severity of early toxicities such as cytokine release syndrome and neurotoxicity.

❓More data needed to better characterize how ICIs impact CAR T-cell function and TME in patients with PMBCL

🙏All collaborators and co-authors @mshadman @fredhutch @NatalieGroverMD @BradHaverkos @DrMarcosdelima @AMalone2012 @LauriePearsonMD @AnnaSureda5 @Kwudhikarn @samyamshon + others not on X.
Special thanks to @MediHumdani @MedicalCollege and Senior Author Dr. Alex Herrera @cityofhope for their guidance and for putting up with me! 😅

👉Please share with your network if you learnt something with this post 🙏
#HemOnc #MedEd #lymphomasm #CARTcelltherapy

[Ariel Perez @app1279]

I am thrilled to announce my promotion to Medical Director of Cellular Therapy. It has been an amazing 4 years since I joined @BaptistHealthSF. I am looking forward to continue developing the Miami Cancer Institute adoptive cell therapy program with our amazing team and leaders.

[Frederick L. Locke @DrFredLocke]

@BLLPHD Finally, awake after a long REMS slumber!!! @ASTCT

https://t.co/yFk1Gsfjhg

[Rafael Fonseca MD 🦔🇺🇸🏜🇲🇽 @Rfonsi1]

Using CARTs for first relapse in myeloma.
#mmsm
https://t.co/nMbqvRVAXK

[Ariel Perez @app1279]

@KRejeski @Eddie_Cliff @gloria_iacoboni @Kersten_MJ @AnnaSureda5 @i_yakoub_agha @MSubklewe Congrats Kai

[SurvivorNet @SurvivorNetTeam]

Thank you to @MichaelDJain from @MoffittNews for helping us create this guide and sharing his insights on life after lymphoma. #lymsm